Abstract:Proteins of the Bcl-2 family are key regulators of caspase activation and apoptosis. Some members of this family, notably Bcl-2 and Bcl-xL, are overexpressed in cancer cells, which have been associated with chemoresistance. We have designed and synthesized a small molecule inhibitor of Bcl-2, named YC137, and studied its role in cancer cells. In vitro studies showed that YC137 inhibits the binding of the Bid BH3 peptide to Bcl-2, thus disrupting an interaction essential for the antiapoptotic activity of Bcl-2. This inhibitor induces apoptosis of hematopoietic progenitors overexpressing Bcl-2 but not Bcl-xL and breast cancer cells that express high levels of Bcl-2. On the contrary, a variety of normal primary cells, including CD34+ progenitors, myoblasts, and peripheral blood mononuclear cells, do not respond to the inhibitor. A breast cancer cell line resistant to YC137 was generated. Analysis of resistant cells revealed a reduced expression of Bcl-2, which correlated with low activation of signal transducer and activator of transcription-3 (Stat3) and reduced expression of the human epidermal growth factor receptor-2 (HER2). Of note, YC137-resistant cells were more sensitive to apoptosis induced by chemotherapy. Because HER2 has not been linked previously to the Stat3-Bcl-2 transcriptional pathway, we additionally confirmed that specific blockade of HER2 in breast cancer cells resulted in down-regulation of Stat3 activity and reduced levels of Bcl-2. Consistently, HER2 blockade led to YC137 resistance. These data provide evidence for the selective killing of tumor cells by YC137 and represent the first example of in vitro selection of cancer cells refractory to a Bcl-2 inhibitor.

CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth

Bh4 Domain Of Bcl-2 As A Novel Target For Cancer Therapy

Abstract 2922: Development of Bcl2 BH4 Antagonist for Cancer Therapy

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.

Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain

A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma

BCL2-BH4 Antagonist BDA-366 Suppresses Human Myeloma Growth

BCL-2 Isoform Β Promotes Angiogenesis by TRiC-mediated Upregulation of VEGF-A in Lymphoma

Discovery and development of substituted tyrosine derivatives as Bcl-2/Mcl-1 inhibitors.

Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy

Bcl-2 Family Proteins As Targets for Anticancer Drug Design

B-cell Lymphoma-2 Family Proteins in the Crosshairs: Small Molecule Inhibitors and Activators for Cancer Therapy.

Inhibitors of BCL2A1/Bfl-1 Protein: Potential Stock in Cancer Therapy.

Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells

Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by A Novel Small Molecule Inhibitor of Bcl-2

BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo

Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy

Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction

The Bispecific Antibody HB-32, Blockade of Both VEGF and DLL4 Shows Potent Anti-Angiogenic Activity in Vitro and Anti-Tumor Activity in Breast Cancer Xenograft Models.